-
Mashup Score: 2FDA Approves Momelotinib in Patients with Myelofibrosis with Anemia | Blood Cancers Today - 1 year(s) ago
The FDA approval of momelotinib is supported by data from the pivotal MOMENTUM study and a subpopulation of adult patients with anemia from the SIMPLIFY-1 phase III trial.
Tweet
The Fellow on Call: The Heme/Onc Podcast
Oncology / HematologyThe Fellow on Call: The Heme/Onc Podcast is dedicated to bringing its listeners the fundamentals, core concepts, and important management approaches in the field of hematology and oncology, driven by the latest evidence and expert opinion. In each episode, the hosts provide answers to common questions in a way that is perfect for anyone interested in hematology and oncology, from students and trainees to nurses, advanced practice providers, and practicing physicians.
-
Mashup Score: 16Episode 072: Introduction to Diffuse Large B-Cell Lymphoma (DLBCL) — The Fellow On Call - 1 year(s) ago
Episode 072: Introduction to Diffuse Large B-Cell Lymphoma (DLBCL) This week, we kick off a new series focusing on diffuse large B-cell lymphoma. In this first episode, we discuss the basics that everyone needs to understand before diving into the management of this disease.
Tweet-
As we mentioned in the introduction above, our latest series covers the ins-and-outs of diffuse large B-cell lymphoma (DLBCL). Start your journey through this complex, but incredibly high yield disease, with our introduction episode. Through the link here, you will also be able to find subsequent episodes!
-
-
Mashup Score: 6Episode 071: Heme Consults Series: Heparin-induced thrombocytopenia (A deeper dive!) — The Fellow On Call - 1 year(s) ago
Episode 071: Heme Consults Series: Heparin-induced thrombocytopenia (A deeper dive!) We revisit a topic covered previously as part of our “Heme/Onc Emergencies” series: heparin-induced thrombocytopenia (HIT) in Episode 017. As part of our return, we dive deeper into the pathophysiology, principles
Tweet-
If you have done an inpatient hematology consult rotation, you likely have had a consult requesting assistance for the workup and management of suspected heparin-induced thrombocytopenia (HIT). But what is HIT? What is the pathophysiology? And how do we work this up? We break this down in this episode.
-
-
Mashup Score: 103Erik K Singhi, MD on Twitter - 1 year(s) ago
Lung cancer STAGING takes the CENTER STAGE at #WCLC23 9th edition updates: T: No changes N: N2 N2a (station N2) & N2b (Multistation N2) M: M1c M1c1 (Multi extrathoracic mets,organ) & M1c2 (Multi extrathoracic mets, multiple organs) @OncoAlert @IASLC #lcsm
Source: The Fellow On CallCategories: Hem/Oncs, Latest HeadlinesTweet-
In case you missed it, the IASLC 2023 World Conference on Lung Cancer (WCLC) just happened a few weeks back, held in beautiful Singapore. Amongst the topics of discussion were changes to the TNM staging for lung cancer. Although these have not been formally announced, definitely worth noting and keeping an eye out for!
-
-
Mashup Score: 124Rami Manochakian, MD on Twitter - 1 year(s) ago@OncoAlert Hot off the press, presented @IASLC #WCLC23, results of #FLAURA2 trial showed statistically significant & clinically meaningful #PFS benefit of #Osimertinib + Chemo vs #Osimertinib alone, as 1st line Treatment in Patients with #EGFRm Advanced #NSCLC. mPFS: By investigator; 25.5 vs 16.7 months HR: 0.62 By BICR; 29.4 vs 19.9 months HR: 0.62 OS data immature Grade ≥3 AEs (Osi + chemo vs Osi) 64% vs 27%Source: The Fellow On CallCategories: Hem/Oncs, Latest HeadlinesTweet
-
You may recall that in Episode 033 of The Fellow on Call, we discussed the use of osimertinib, an tyrosine kinase inhibitor specific for EGFR, as the standard of care for patients with metastatic non-small cell lung cancer (https://www.thefellowoncall.com/tfocpodcast/jt7mmp342rn85wy-stczg), based on the results of the FLAURA study. At the recent WCLC, results of the FLAURA2 study were shared, highlighting improvements in PFS when osimertinib was combined with chemotherapy. This is most definitely exciting, but what remains to be seen is if we can better identify who would benefit from this the most. As the study shows, there was more toxicity associated with the addition of chemotherapy!
-
Momelotinib has been approved by the Food and Drug Administration for the treatment of patient with myelofibrosis with anemia. The mechanism of action is quite interesting and worth noting, as highlighted in the MOMENTUM trial. Momelotinib not only inhibits JAK1 and JAK2, which subsequently helps with inflammation reduction, decreased cytokine release, and splenomegaly, but it also inhibits ACVR1, which suppresses the potent iron regulator, hepcidin. Therefore, this permits more iron availability for hematopoiesis. Very cool stuff!